Arsenoplatins are adducts of two chemically important anticancer drugs, cisplatin and arsenic trioxide, that have a Pt(II) bond to an As(III) hydroxide center. Screens of the NCI-60 human tumor cell lines reveal that arsenoplatin-1 (AP-1), [Pt(μ-NHC(CH 3 )O) 2 ClAs(OH) 2 ], the first representative of this novel class of anticancer agents, displays a superior activity profile relative to the parent drugs As 2 O 3 or cisplatin in a majority of cancer cell lines tested. These activity profiles are important because the success of arsenic trioxide in blood cancers (such as APL) has not been seen in solid tumors due to the rapid clearance of arsenous acid from the body. To understand the biological chemistry of these compounds, we evaluated interactions of AP-1 with the two important classes of biomolecules - proteins and DNA. The first structural studies of AP-1 bound to model proteins reveal that platinum(II) binds the Nμ of His in a manner that preserves the Pt-As bond. We find that AP-1 readily enters cells and binds to DNA with an intact Pt-As bond (Pt:As ratio of 1). At longer incubation times, however, the Pt:As ratio in DNA samples increases, suggesting that the Pt-As bond breaks and releases the As(OH) 2 moiety. We conclude that arsenoplatin-1 has the potential to deliver both Pt and As species to a variety of hematological and solid cancers.

Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent

Marzo, Tiziano;
2019-01-01

Abstract

Arsenoplatins are adducts of two chemically important anticancer drugs, cisplatin and arsenic trioxide, that have a Pt(II) bond to an As(III) hydroxide center. Screens of the NCI-60 human tumor cell lines reveal that arsenoplatin-1 (AP-1), [Pt(μ-NHC(CH 3 )O) 2 ClAs(OH) 2 ], the first representative of this novel class of anticancer agents, displays a superior activity profile relative to the parent drugs As 2 O 3 or cisplatin in a majority of cancer cell lines tested. These activity profiles are important because the success of arsenic trioxide in blood cancers (such as APL) has not been seen in solid tumors due to the rapid clearance of arsenous acid from the body. To understand the biological chemistry of these compounds, we evaluated interactions of AP-1 with the two important classes of biomolecules - proteins and DNA. The first structural studies of AP-1 bound to model proteins reveal that platinum(II) binds the Nμ of His in a manner that preserves the Pt-As bond. We find that AP-1 readily enters cells and binds to DNA with an intact Pt-As bond (Pt:As ratio of 1). At longer incubation times, however, the Pt:As ratio in DNA samples increases, suggesting that the Pt-As bond breaks and releases the As(OH) 2 moiety. We conclude that arsenoplatin-1 has the potential to deliver both Pt and As species to a variety of hematological and solid cancers.
2019
Miodragović, Denana; Merlino, Antonello; Swindell, Elden P.; Bogachkov, Abraham; Ahn, Richard W.; Abuhadba, Sara; Ferraro, Giarita; Marzo, Tiziano; Mazar, Andrew P.; Messori, Luigi; O'Halloran, Thomas V.
File in questo prodotto:
File Dimensione Formato  
Arsenoplatin-1 is a Dual Pharmacophore Anti-Cancer Agent.pdf

non disponibili

Descrizione: Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent_editorial
Tipologia: Versione finale editoriale
Licenza: NON PUBBLICO - accesso privato/ristretto
Dimensione 1.52 MB
Formato Adobe PDF
1.52 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/990263
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 37
social impact